Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The burden of polypharmacy in patients with chronic kidney disease (CKD) is substantial and exceeds most other chronic diseases. Clinicians and patients are often reluctant to add new medications to already complex treatment regimens, partly due to concerns about diminishing efficacy and increased adverse effects, contributing to underuse of guideline directed medical therapies. We assessed whether the efficacy and safety of canagliflozin is modified by polypharmacy status in patients with type 2 diabetes and CKD.
We conducted a post-hoc analysis of the CREDENCE trial, which evaluated the effects of canagliflozin on clinical outcomes in participants with type 2 diabetes and albuminuric CKD. Participants were categorized according to polypharmacy status at baseline: no polypharmacy (0-4 medicines), polypharmacy (5-9 medicines), and hyperpolypharmacy (≥10 medicines). We assessed the relative effects of canagliflozin on kidney, cardiovascular and safety outcomes by baseline polypharmacy status using Cox proportional hazards models. We assessed absolute benefits and harms, expressed as the number of events averted or caused per 1000 patient-years using Poisson regression. The primary outcome was a composite of doubling of serum creatinine, kidney failure or death due to cardiovascular or kidney disease.
Among 4401 participants, 612 (14%), 2404 (55%), and 1385 (31%) were categorized as no polypharmacy, polypharmacy and hyperpolypharmacy, respectively. The mean number of medications at baseline was 8.3 (95% CI 8.2-8.4). Those with polypharmacy and hyperpolypharmacy were more likely to be older, male, and to have atherosclerotic cardiovascular disease and a longer duration of diabetes, higher body mass index, systolic blood pressure, and lower eGFR. The effect of canagliflozin on all kidney and cardiovascular outcomes was consistent irrespective of polypharmacy status (all p-interaction >0.05; Figure 1), with no interaction observed for safety outcomes (all p-interaction >0.05). While rates of treatment discontinuation were higher with increasing medication burden, treatment discontinuation was consistently lower with canagliflozin versus placebo, regardless of polypharmacy status (HR 0.80, 95% CI 0.71-0.89, p-interaction 0.16). Because the overall incidence of all-cause hospitalization increased with higher medication burden, absolute risk reductions with canagliflozin treatment were considerably higher in patients experiencing polypharmacy and hyperpolypharmacy (Figure 2). Regardless of polypharmacy status, absolute benefits substantially outweigh any harms defined by DKA, amputation, or volume depletion (Figure 2).
In patients with type 2 diabetes and CKD, the net absolute benefits of canagliflozin exceed the serious harms analyzed, irrespective of polypharmacy status. Larger absolute reductions in all-cause hospitalization were observed in those experiencing polypharmacy or hyperpolypharmacy. Polypharmacy should not dissuade clinicians from using an SGLT2 inhibitor in patients with CKD for whom treatment is indicated.
